Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses

Simply Wall St.07-18 10:17

Alnylam Pharmaceuticals (ALNY) is drawing attention after advancing its Alzheimer’s disease pipeline by initiating a Phase 2 trial of mivelsiran in Down syndrome-associated Alzheimer’s and completing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652236096?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-18 10:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652236096","market":"nz","top_or_hot":-1,"title":"Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses","media":"Simply Wall St.","content":"<div>\n<p>Alnylam Pharmaceuticals (ALNY) is drawing attention after advancing its Alzheimer’s disease pipeline by initiating a Phase 2 trial of mivelsiran in Down syndrome-associated Alzheimer’s and completing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-could-be-39-below-fair-value-as\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-18 10:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-could-be-39-below-fair-value-as><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alnylam Pharmaceuticals (ALNY) is drawing attention after advancing its Alzheimer’s disease pipeline by initiating a Phase 2 trial of mivelsiran in Down syndrome-associated Alzheimer’s and completing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-could-be-39-below-fair-value-as\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0882574055.USD","symbol_name":"富达全球健康医疗A ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-could-be-39-below-fair-value-as","article_id":"2652236096","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-could-be-39-below-fair-value-as","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2652236096","pubTimestamp":1784341077,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Alnylam Pharmaceuticals (ALNY) is drawing attention after advancing its Alzheimer’s disease pipeline by initiating a Phase 2 trial of mivelsiran in Down syndrome-associated Alzheimer’s and completing enrollment in a related cerebral amyloid angiopathy study.\nSee our latest analysis for Alnylam Pharmaceuticals.\nDespite the Alzheimer’s updates, Alnylam Pharmaceuticals’ share price has come under pressure, with the stock down 10.47% over the past week and 33.16% on a year to date share price...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0882574055.USD":"富达全球健康医疗A ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4585":"ETF&股票定投概念","ALNY":"阿尔尼拉姆制药公司","BK4548":"巴美列捷福持仓","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"随着阿尔茨海默病管道的进展，Alnylam Pharmaceuticals (ALNY) 的股价可能比公允价值低 39%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PBE":0.6,"ALNY":1.5},"content_text":"Alnylam Pharmaceuticals (ALNY) is drawing attention after advancing its Alzheimer’s disease pipeline by initiating a Phase 2 trial of mivelsiran in Down syndrome-associated Alzheimer’s and completing enrollment in a related cerebral amyloid angiopathy study. See our latest analysis for Alnylam Pharmaceuticals. Despite the Alzheimer’s updates, Alnylam Pharmaceuticals’ share price has come under pressure, with the stock down 10.47% over the past week and 33.16% on a year to date share price return. However, the 5 year total shareholder return of 46.63% points to longer term momentum that has previously rewarded patient holders. If this kind of neuroscience pipeline progress interests you, it can be worth widening the lens to other potential opportunities in healthcare AI, starting with the 39 healthcare AI stocks After a sharp recent pullback, Alnylam Pharmaceuticals now trades at a sizeable discount to both analyst targets and intrinsic value estimates. Is that pricing in genuine pipeline risk, or has caution swung too far, too fast? AdvertisementMost Popular Narrative: 38.5% Undervalued With Alnylam Pharmaceuticals last closing at $267.47 against a narrative fair value of $434.72, the current price reflects a sizable gap that the most followed thesis tries to explain.  The rapid and robust uptake of AMVUTTRA for ATTR-CM in its first full quarter post-approval, combined with near-universal first-line payer access and minimal patient out-of-pocket costs, indicates a much larger addressable market for Alnylam's RNAi therapies as diagnostics and disease awareness improve, supporting sustained double-digit revenue growth. International expansion for AMVUTTRA in major markets (Germany, Japan, Brazil, EU) is only just starting and is expected to contribute meaningful incremental revenue in the second half of the year and beyond, with global rollouts benefiting from favorable reimbursement dynamics for high-impact orphan drugs.  Read the complete narrative. Curious what earnings path and margin profile could justify that higher fair value for Alnylam Pharmaceuticals? The narrative leans on brisk revenue growth, rising profitability and a rich future earnings multiple that many investors usually associate with faster growing sectors. The exact mix of those assumptions might surprise you. Result: Fair Value of $434.72 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Alnylam Pharmaceuticals still faces two clear swing factors: execution on its TTR franchise and potential pricing or reimbursement pressure on key RNAi therapies. Find out about the key risks to this Alnylam Pharmaceuticals narrative. Another View on Alnylam Pharmaceuticals’ Valuation While the narrative fair value of $434.72 frames Alnylam Pharmaceuticals as 38.5% undervalued, the current P/E of 66.4x tells a much tougher story. It is far above the US Biotechs industry at 17.1x, the peer average of 31.8x, and even its own fair ratio of 34.6x. This points to meaningful valuation risk if sentiment cools. That kind of premium raises a simple question for you as an investor: are you being paid enough in potential upside to accept the risk that the market could drift back toward the fair ratio or closer to industry and peer levels over time? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ALNY P/E Ratio as at Jul 2026Next Steps Feeling cautious or optimistic after looking at Alnylam Pharmaceuticals so far? Act while sentiment is in flux by reviewing the 4 key rewards Looking for more investment ideas beyond Alnylam Pharmaceuticals? If you like the kind of detail you have seen on Alnylam Pharmaceuticals, do not stop here. The next strong opportunity could already be on your radar.  Target potential bargains early by checking companies that screen as attractively valued through the 47 high quality undervalued stocks. Strengthen your income toolkit by scanning for companies with strong yields and resilience using the 8 dividend fortresses. Reduce portfolio stress by focusing on companies that score well on financial resilience through the 84 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652236096","isCrawlerRequest":true}